CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Notably, in vivo administration of VK3 in wild-type mice did not alter the frequency of HSCs in bone marrow, and human CD34+ CML cells treated with VK3 in vitro did not show significant apoptosis, suggesting that VK3 might not have toxic effects on steady-state hematopoiesis.